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Introduction: Thoracic radiotherapy (RT) with concurrent chemo-
therapy may be offered to selected elderly patients with locally
advanced non-small cell lung cancer. The Okayama Lung Cancer
Study Group (OLCSG) 0007 trial with patients up to 75 years
showed that with concurrent RT, docetaxel and cisplatin (DP)
chemotherapy was an alternative to mitomycin C, vindesine, and
cisplatin (MVP) chemotherapy.
Methods: Of the 99 patients in the DP arm, 73 were younger than
70 years and 26 were 70 years or older. Of the 101 patients in the
MVP arm, 75 were younger than 70 years and 26 were 70 years or
older. Overall survival (OS) and progression-free survival (PFS)
were calculated using the Kaplan-Meier method and were compared
using an early period weighted log-rank test. Toxicities and treat-
ment intensities were compared by 2 and t tests, respectively.
Results: OS and PFS tended to be longer in the DP arm versus MVP
arm: median OS (months), 27.5 versus 22.9 (p  0.109) and 25.6
versus 23.4 (p  0.064) in the 70-year and 70-year groups,
respectively; median PFS (months), 19.0 versus 11.5 (p  0.175)
and 12.0 versus 9.3 (p  0.132) in the 70-year and less than
70-year groups, respectively. Severe toxicity (neutropenia, esoph-
agitis, and pneumonitis) rates did not differ between age groups.
Nevertheless, the absence of statistically significant differences in
this retrospective analysis might be due to the small number of
patients. Radiation intensity was similar between the groups, but
chemotherapy intensity was lower in the 70-year group.
Conclusion: Chemotherapy with concurrent RT may be effective
and tolerable in elderly patients with locally advanced non-small cell
lung cancer.
Key Words: Non-small cell lung cancer, Elderly, Radiation,
Chemotherapy.
(J Thorac Oncol. 2011;6: 1087–1091)
In locally advanced non-small cell lung cancer (LA-NSCLC), cisplatin-based chemotherapy with concurrent
thoracic radiotherapy (RT) is the standard treatment.1 Never-
theless, six prospective phase II and III studies revealed that
patients older than 70 years manifested the best quality-
adjusted survival with standard RT alone, compared with
induction chemotherapy followed by RT, concurrent chemo-
radiotherapy, or hyperfractionated RT.2 Sause et al.3 also
reported that the survival of patients older than 70 years was
higher with standard RT alone, with a median survival time
(MST) of 13.1 months, compared with induction chemother-
apy followed by RT or hyperfractionated RT. Although this
*Department of Respiratory Medicine, Okayama University Hospital,
Okayama; †Department of Medicine and Thoracic Oncology, NHO
Shikoku Cancer Center, Matsuyama; ‡Department of Internal Medicine,
Okayama Red Cross Hospital, Okayama; §Department of Internal Med-
icine, Tsuyama Central Hospital, Tsuyama; Department of Internal
Medicine, Kagawa Rosai Hospital, Marugame; ¶Department of Internal
Medicine, Okayama Saiseikai General Hospital, Okayama; #Department
of Internal Medicine, Okayama Rosai Hospital, Okayama; **Department
of Internal Medicine, Ehime Prefectural Central Hospital, Matsuyama;
††Department of Internal Medicine, Kure Kyosai Hospital, Kure; ‡‡De-
partment of Internal Medicine, Tottori Municipal Hospital, Tottori;
§§Department of Internal Medicine, Kawasaki Hospital, Okayama; De-
partment of Radiology, Okayama University Hospital, Okayama; ¶¶De-
partment of Epidemiology and Prevention, Aichi Cancer Center Research
Institute, Nagoya; and ##Department of Medicine, NHO Yamaguchi-Ube
Medical Center, Ube, Japan.
Disclosure: Drs. Takigawa, Kiura and Ueoka were paid an honorarium for
lecturing from Sanofi-aventis, Japan. The other authors declare no con-
flicts of interest.
Address for correspondence: Nagio Takigawa, MD, PhD, Department of
Respiratory Medicine, Okayama University Hospital, 2-5-1 Shikata-
cho, Kitaku, Okayama 700-8558, Japan. E-mail: ntakigaw@md.
okayama-u.ac.jp
Copyright © 2011 by the International Association for the Study of Lung
Cancer
ISSN: 1556-0864/11/0606-1087
Journal of Thoracic Oncology • Volume 6, Number 6, June 2011 1087
study did not present a toxicity profile according to age
groups, 2 of the 22 patients receiving chemotherapy followed
by RT experienced toxic death.
Langer et al.4,5 retrospectively analyzed three phase II/III
trials using RT, sequential chemoradiotherapy, and concurrent
chemoradiotherapy. Patients older than 70 years did not benefit
from concurrent chemoradiotherapy or sequential chemoradio-
therapy compared with RT alone. As the therapy intensified, the
incidence of grade 3 to 5 toxicities increased. No grade 4 and 5
toxicities occurred in any patients older than 70 years who
received RT alone, whereas 19% of those receiving chemora-
diotherapy showed grade 4 and 5 toxicities.
Atagi et al. performed a phase III study of RT with and
without daily carboplatin for LA-NSCLC in patients older
than 70 years. Although MST appeared to be better in the RT
with carboplatin arm (18.4 months) than in the RT-alone arm
(14.3 months), the study was terminated early, owing to a
high proportion of treatment-related deaths due to radiation
pneumonitis and protocol violation.6 Taken together, these
previous studies suggest that chemoradiotherapy may be
beneficial for selected elderly patients; however, RT alone
was considered to be the standard treatment in elderly LA-
NSCLC patients.
We previously conducted a phase III trial (OLCSG 0007)
comparing docetaxel and cisplatin (DP) combination chemo-
therapy to mitomycin C, vindesine, and cisplatin (MVP) com-
bination chemotherapy, both with concurrent RT, in LA-
NSCLC patients up to the age of 75 years.7 The survival time at
2 years was longer in the DP arm, and the survival rate at 2 years
was higher in the DP arm (60.3%) than in the MVP arm
(48.1%). The MST in the DP arm was 26.8 months compared
with 23.7 months in the MVP arm. Grade 3 or higher hemato-
logical toxicity and febrile neutropenia were seen significantly
more often in patients in the MVP arm compared with the DP
arm. The incidence of radiation esophagitis (grade 3) was
higher in the DP arm (14%) than in the MVP arm (6%), but the
difference was not significant. In this study, we performed a
secondary analysis of the OLCSG 0007 trial by comparing the
benefits and adverse events between younger patients (younger
than 70 years) and older patients (70 years or older).
METHODS
The methods used were as described earlier.7 Briefly,
eligible patients (75 years or younger) with unresectable IIIA or
IIIB NSCLC and Eastern Cooperative Oncology Group perfor-
mance status (PS) 0 or 1 were randomly assigned to the DP or
MVP treatment arms by the administrative office (Aichi Cancer
Center, Nagoya, Japan) according to stratification for the PS (0
versus 1) and clinical stage (IIIA versus IIIB). Institution was an
adjustment factor in the dynamic allocation. In the DP arm,
docetaxel (40 mg/m2) was administered intravenously, followed
by cisplatin (40 mg/m2), on days 1, 8, 29, and 36. In the MVP
arm, Mitomycin C (8 mg/m2) and cisplatin (80 mg/m2) were
infused on days 1 and 29, and vindesine (3 mg/m2) was infused
on days 1, 8, 29, and 36. Concurrent RT began on day 1 of
chemotherapy and was given in daily radiation doses of 2 Gy for
5 consecutive days every week for a total dose of 60 Gy. A
curative radiation field was constructed using a plain chest
radiograph and a contrast-enhanced computed tomography (CT)
scan. The initial dose (40 Gy) was administered to the primary
tumor, the ipsilateral hilum with a 2-cm margin, and the in-
volved mediastinal lymph nodes with a 1-cm margin. Prophy-
lactic radiation fields were not planned, except for subcarinal
lymph nodes. The chemotherapy and RT doses and schedules
were modified in cases of toxicity, as described previously. The
protocol was approved by institutional review boards and/or an
ethical committee, and all patients provided written informed
consent.
The treatment response was assessed by extramural
reviewers using the Response Evaluation Criteria in Solid
Tumors (RECIST). Toxicity was assessed and graded using
the National Cancer Institute Common Toxicity Criteria tox-
icity scale version 2. The RT and chemotherapy dose inten-
sities indicate the administered dose per time unit/projected
dose per time unit. The treatment response and survival time
were determined on an intent-to-treat basis. Overall survival
(OS) time was calculated from randomization to death. Pro-
gression-free survival (PFS) time was calculated from ran-
domization to progressive disease or death caused by condi-
tions other than NSCLC.
Toxicities and treatment intensities were compared by
2 and t tests, respectively. Survival analysis was planned at
2 years after the last patient began the study. Differences in
survival times were evaluated using the modified stratified
log-rank test proposed by Fleming-Harrington to allow for a
weighted difference during the observation period.8 As the
primary end point was the comparison of 2-year survival
rates, earlier observation periods were given a higher weight
than later periods. The stratification factors were Eastern
Cooperative Oncology Group PS, clinical stage, and institute.
Values of p less than 0.05 for a two-sided test were consid-
ered to indicate statistical significance. Similar analyses were
used to evaluate PFS.
RESULTS
Between July 2000 and July 2005, 200 patients partic-
ipated in the OLCSG 0007 trial. Of the 99 patients in the DP
arm, 73 patients were younger than 70 years and 26 were 70
years or older. Of the 101 patients in the MVP arm, 75
patients were younger than 70 years and 26 were 70 years or
older. Table 1 lists the characteristics of the patient groups.
Treatment-related toxicities by age group in each arm
are listed in Table 2. The incidence of grade 3 or higher
hematological toxicities, febrile neutropenia, esophagitis, and
pneumonitis was not significantly different between the two
age groups although the incidence of pneumonitis tended to
be higher in the older patient group (p  0.448 in DP arm,
p  0.362 in MVP arm, and p  0.148 in total). In the DP
arm, the incidences of pneumonitis (3 grade, acute versus
late) were 5 versus 1 in the younger group and 2 versus 2 in
the older group. In the MVP arm, they were 4 versus 0 in the
younger group and 1 versus 2 in the older group. There were
four treatment-related deaths. In the DP arm, two patients
(72- and 73-year-old) died of late pneumonitis, and a 75-year-
old patient died of sepsis. In the MVP arm, a 46-year-old
patient died of pneumonia with pneumothorax.
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As shown in Table 3, the total RT doses and intensities
were equivalent between the age groups in each arm. The
projected RT dose was completed in 84% of DP arm and 83%
of MVP arm in the younger patients and 92% of DP arm and
96% of MVP arm in the older patients. In the DP arm,
cisplatin and docetaxel dose intensities were significantly
lower in the older group compared with the younger group
(p  0.001 and 0.019, respectively), and the dose intensity of
mitomycin in the MVP arm was significantly lower in the
older group (p  0.043). The cisplatin and vindesine dose
intensities were lower in the older group, but the difference
between age groups was not significant. The projected che-
motherapy regimen was completed in 85% of DP arm and in
77% of MVP arm in the younger patients and in 62% of DP
arm and in 76% of MVP arm in the older patients.
The response rate was 79% in the DP arm (78% in the
70-year group and 81% in the 70-year group; p  0.88)
and 75% in the MVP arm (69% in the 70-year group and
76% in the 70-year group; p  0.74). The OS and PFS
tended to be higher in the DP arm than in the MVP arm
(Figure 1), and the MST and median PFS time (Table 4)
TABLE 1. Patient Characteristics by Age Group and
Treatment Arm
Characteristic
DP Treatment
Arm Age
Group (yr)
MVP
Treatment
Arm Age
Group (yr)
<70 >70 <70 >70
No. of patients 73 26 75 25
Gender
Male 67 (92) 25 (96) 67 (89) 20 (80)
Female 6 (8) 1 (4) 8 (11) 5 (20)
Performance status
0 34 (47) 12 (46) 32 (43) 18 (72)
1 39 (53) 14 (54) 43 (57) 7 (28)
Stage
IIIA 24 (33) 10 (38) 23 (31) 9 (36)
IIIB 49 (67) 16 (62) 52 (69) 16 (64)
Body weight loss
0–4% 62 (85) 25 (96) 65 (87) 24 (96)
5% or more 11 (15) 1 (1) 10 (13) 1 (4)
Values are expressed as number (%).
DP, cisplatin and docetaxel; MVP, mitomycin C, vindesine, and cisplatin.
TABLE 2. Toxicity by Age Group and Treatment Arm
Toxicity by Grade
DP Age
Group (yr)
MVP Age
Group (yr)
Total
(DPMVP)
Age Group (yr)
<70 >70 <70 >70 <70 >70
No. of patients 73 26 75 25 148 51
Leucopenia
3 20 (27) 6 (23) 3 (4) 1 (4) 23 (16) 7 (14)
3–5 53 (73) 20 (77) 72 (96) 24 (96) 125 (84) 44 (86)
Neutropenia
3 30 (41) 8 (31) 3 (4) 3 (12) 33 (22) 11 (22)
3–5 43 (59) 18 (69) 72 (96) 22 (88) 115 (78) 40 (78)
Thrombocytopenia
3 72 (99) 25 (96) 58 (77) 17 (68) 130 (88) 42 (82)
3–5 1 (1) 1 (4) 17 (23) 8 (32) 18 (12) 9 (18)
Febrile neutropenia
3 55 (75) 23 (88) 44 (59) 16 (64) 99 (67) 39 (76)
3–5 18 (25) 3 (12) 31 (41) 9 (36) 49 (33) 12 (24)
Esophagitis
3 61 (84) 24 (92) 70 (93) 24 (96) 131 (89) 48 (94)
3–5 12 (16) 2 (8) 5 (7) 1 (4) 17 (11) 3 (6)
Pneumonitis
3 67 (92) 22 (85) 71 (95) 22 (88) 138 (93) 44 (86)
3–5 6 (8) 4 (15) 4 (5) 3 (12) 10 (7) 7 (14)
Values are expressed as number (%).
DP, cisplatin and docetaxel; MVP, mitomycin C, vindesine, and cisplatin.
TABLE 3. Radiation and Chemotherapy Dose Intensities by
Age Group and Treatment Arm
Parameter
DP Age
Group (yr)
MVP Age
Group (yr)
<70 >70 <70 >70
No. of patients 73 26 75 25
Total RT dose (Gy) 58.5  3.8 59.6  2.0 59.2  3.4 59.9  0.4
p 0.169 0.317
RT intensity (%) 95  11 93  14 86  11 84  13
p 0.633 0.691
CDDP dose intensity (%) 87  18 72  22 91  12 86  14
p 0.001 0.106
DOC dose intensity (%) 87  18 76  23
p 0.019
VDS dose intensity (%) 88  15 82  19
p 0.068
MMC dose intensity (%) 92  12 86  15
p 0.043
Intensity is presented as mean  SD. RT or chemotherapy dose intensities indicate
administered dose per time unit/projected dose per time unit. p values are for the
differences in parameters between age groups by each treatment arm.
DP, cisplatin and docetaxel; MVP, mitomycin C, vindesine, and cisplatin; RT,
radiotherapy; CDDP, cisplatin; DOC, docetaxel; VDS, vindesine; MMC, mitomycin C.
FIGURE 1. Overall survival of patients in the two randomly
assigned treatment arms according to age group (younger
than 70 years versus 70 years or older).
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tended to be longer in the DP arm than in the MVP arm
irrespective of age group, although the differences between
arms were not significant. In the DP arm, MST (27.5 months)
and median PFS time (19.0 months) tended to be longer in
older patients than in younger patients.
DISCUSSION
In this study, there was no significant difference in
OS or PFS between the two age groups according to
treatment arm, although OS and PFS tended to be higher in
the DP arm than in the MVP arm by the modified stratified
log-rank test.8 In the DP arm, MST and median PFS time
tended to be longer in older patients than in younger
patients. There was no difference in the rate of severe
toxicity (leucopenia, neutropenia, thrombocytopenia, fe-
brile neutropenia, and esophagitis) between the age
groups. The increase of pneumonitis rate was observed in
the elderly patients, although the differences were not
significant and the numbers were small. Radiation intensity
was equivalent between the two groups, but the chemo-
therapy intensity was lower in the older group. The lower
dose intensities for cytotoxic drugs were likely to be due to
hematological toxicities rather than renal toxicities, be-
cause only one patient (56-year-old) in MVP arm experi-
enced renal toxicity more than grade 2.
Gridelli et al.5 reviewed the benefits and toxicities of
chemoradiotherapy, comparing older and younger patients.
Subanalysis of the Radiation Therapy Oncology Group 94-10
trial showed that MST in patients 70 years or older was
longer with concurrent, rather than sequential, chemoradio-
therapy, but the difference was not significant.9 Acute toxic-
ities, including neutropenia and esophagitis, were more com-
mon in the older age group, but long-term toxicity rates were
similar between older and younger patients.
Schild et al.10 reported a secondary analysis of a phase
III study comparing radiation schedules (twice versus once
daily) with concurrent chemotherapy. Patients aged 70 years
or older had survival rates equivalent to those in the younger
age group, despite increased toxicities, which included my-
elosuppression and pneumonitis. Rocha Lima et al.11 evalu-
ated the effect of age on outcome in two chemoradiotherapy
trials conducted by the Cancer and Leukemia Group B.
Compared with younger patients, older patients (70 years or
older) had a significantly higher incidence of grade 3
neutropenia and renal toxicity but similar survival time. In
this study, the incidence of severe toxicity (grade 3 versus
grade 3–5) did not differ between the age groups, although
the incidence of pneumonitis tended to be higher in the
elderly. Toxicities of chemoradiation for NSCLC are in to a
substantial extent determined by planning target volume
(PTV). It is possible that there was a relationship between
grade of pneumonitis and PTV in this study. Unfortunately,
PTV was not calculated in all the institutions because CT
simulation was not mandatory for this trial. Approximately
two-thirds of the institutes used CT simulation to construct
the radiation field at the beginning of this trial. Accordingly,
when modern radiation technologies are used, the relation-
ship between toxicities and PTV should be evaluated in the
future trial.
Kudoh et al. reported that compared with vinorelbine,
docetaxel improved the response rate, PFS, and overall dis-
ease-related symptoms in older patients (70 years or older)
with advanced NSCLC. They concluded that docetaxel could
be considered as a mild anticancer treatment option for older
patients.12
This trial has some limitations. The patient number was
small, and the survival times had wide 95% confidence
intervals, especially in the older patient group. In addition,
this trial was not specific for elderly patients, and the upper
age limit was 75 years. Thus, our results should be interpreted
with caution.
In conclusion, chemotherapy with concurrent RT may
be effective and tolerable in elderly patients with LA-
NSCLC. A recent review also showed that concurrent che-
moradiotherapy was offered to selected elderly patients with
LA-NSCLC, as there is a higher risk for toxicity.13 Specific
trials for elderly patients are needed.
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